[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100317723":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":34,"responsibleParty":46,"collaborators":25,"id":50,"slug":25,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":25,"enrollmentInfo":59,"targetDuration":25,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":70,"whyStopped":25,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University of Leeds","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vitamin D","EXPERIMENTAL","4000IU Vitamin D3 as two 50mcg tablets per day",[13],"Dietary Supplement: 4000IU Vitamin D3",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","PLACEBO_COMPARATOR","Placebo - two chewable blackcurrant flavoured tablets per day",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DIETARY_SUPPLEMENT","4000IU Vitamin D3","Chewable blackcurrant flavoured tablets (two per day)",[15,9],null,[27,31],{"name":28,"role":29,"phone":25,"phoneExt":25,"email":30},"Klaus K Witte, MD","CONTACT","k.k.witte@leeds.ac.uk",{"name":32,"role":29,"phone":33,"phoneExt":25,"email":25},"Klaus Witte","00441133926642",[35],{"facility":36,"status":25,"city":37,"state":25,"zip":25,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":25},"Leeds General Infirmary","Leeds","United Kingdom","UK",{"type":41,"coordinates":42},"Point",[43,44],-1.54785,53.79648,{"lat":44,"lon":43},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","KK Witte","Senior Lecturer in Cardiology","100317723",false,"NCT03416361","VItamiN D treatIng Chronic heArT Failure (the Effect of Vitamin D Supplementation in Patients With Heart Failure)","VItamiN D treatIng Chronic heArT Failure (the Effect of Vitamin D Supplementation on Hospitalisation and Mortality in Patients With Heart Failure): Multicentre, Phase III, Randomised Placebo-controlled Trial","VINDICATE2","Inclusion Criteria:\n\n* LVSD (LVEF \\\u003C50%);\n* stable medical and device therapy for \\>3mths;\n* 25\\[OH\\]vitamin D3 \\\u003C50nmol\u002FL\n* At least one of: recent (\\\u003C1 year) hospitalisation for HF, high dose loop diuretic requirement (\\>80mg daily furosemide equiv), diabetes mellitus, ischaemic aetiology\n\nExclusion Criteria:\n\n* Unwilling\u002Funable to sign consent,\n* Severe cognitive impairment,\n* Severe COPD,\n* Anaemia,\n* Other life-threatening co-morbidity (in the opinion of the local co-investigator),\n* Known and active sarcoidosis or tuberculosis","ALL","18 Years",{"count":60,"type":61},1253,"ESTIMATED","INTERVENTIONAL",[64],"NA","VINDICATE 2 will be a randomised, placebo-controlled, parallel group, double-blind study of vitamin D versus placebo in otherwise optimally-managed patients with CHF due to LVSD and vitamin D deficiency (\\\u003C50nmol\u002FL). The intervention will be a daily dose of 4000IU (100µg) per day or matching placebo for a minimum of 2 years and a maximum of 4 years.",[67],"Chronic Heart Failure",[69,9],"Left ventricular dysfunction","NOT_YET_RECRUITING","2022-10-31",{"date":73,"type":74},"2022-11-02","ACTUAL",{"date":76,"type":61},"2023-12-01",{"date":78,"type":61},"2027-03-01",{"name":5,"class":6},1]